HC Wainwright reissued their buy rating on shares of Cynata Therapeutics (OTCMKTS:CYYNF) in a research note issued to investors on Wednesday morning, Zacks.com reports.

Shares of OTCMKTS:CYYNF opened at $1.19 on Wednesday. The company’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.00. Cynata Therapeutics has a 12-month low of $0.75 and a 12-month high of $1.25.

Cynata Therapeutics Company Profile

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease.

Read More: What is a closed-end mutual fund (CEF)?

Receive News & Ratings for Cynata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.